{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:51:45Z","timestamp":1769842305200,"version":"3.49.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1097\/iae.0b013e3181e22659","type":"journal-article","created":{"date-parts":[[2010,9,19]],"date-time":"2010-09-19T18:46:06Z","timestamp":1284921966000},"page":"1609-1615","source":"Crossref","is-referenced-by-count":39,"title":["TWELVE-MONTH OUTCOME AFTER ONE INTRAVITREAL INJECTION OF BEVACIZUMAB TO TREAT MYOPIC CHOROIDAL NEOVASCULARIZATION"],"prefix":"10.1097","volume":"30","author":[{"given":"Jose M","family":"Ruiz-Moreno","sequence":"first","affiliation":[]},{"given":"Javier A","family":"Montero","sequence":"additional","affiliation":[]},{"given":"Luis","family":"Arias","sequence":"additional","affiliation":[]},{"given":"Javier","family":"Araiz","sequence":"additional","affiliation":[]},{"given":"Francisco","family":"Gomez-Ulla","sequence":"additional","affiliation":[]},{"given":"Rufino","family":"Silva","sequence":"additional","affiliation":[]},{"given":"David P","family":"Pi\u00f1ero","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-8-20210130","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00417-006-0472-6","article-title":"Pegaptanib for myopic choroidal neovascularization in a young patient.","volume":"245","author":"Bennett","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R2-8-20210130","first-page":"387","article-title":"[Anty-VEGF therapy in the treatment of myopic macular choroidal neovascularization-cases report].","volume":"110","author":"Figurska","year":"2008","journal-title":"Klin Oczna"},{"key":"R3-8-20210130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00417-008-0995-0","article-title":"Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.","volume":"247","author":"Konstantinidis","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R4-8-20210130","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/IAE.0b013e31817eda41","article-title":"Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization.","volume":"28","author":"Silva","year":"2008","journal-title":"Retina"},{"key":"R5-8-20210130","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/bjo.2007.130260","article-title":"Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results.","volume":"92","author":"Arias","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R6-8-20210130","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.ophtha.2007.03.043","article-title":"Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.","volume":"114","author":"Chan","year":"2007","journal-title":"Ophthalmology"},{"key":"R7-8-20210130","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/bjo.2008.145797","article-title":"Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study.","volume":"93","author":"Chan","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R10-8-20210130","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/01.iae.0000240121.28034.c3","article-title":"Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab.","volume":"26","author":"Laud","year":"2006","journal-title":"Retina"},{"key":"R11-8-20210130","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/112067210701700422","article-title":"Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization.","volume":"17","author":"Mandal","year":"2007","journal-title":"Eur J Ophthalmol"},{"key":"R12-8-20210130","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/bjo.2005.066431","article-title":"Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia.","volume":"89","author":"Nguyen","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R13-8-20210130","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/sj.eye.6703052","article-title":"Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results.","volume":"23","author":"Ruiz-Moreno","year":"2009","journal-title":"Eye"},{"key":"R14-8-20210130","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/bjo.2008.145391","article-title":"Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome.","volume":"93","author":"Ruiz-Moreno","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R15-8-20210130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/bjo.2006.099887","article-title":"Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia.","volume":"91","author":"Sakaguchi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R16-8-20210130","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/01.iae.0000254896.78766.74","article-title":"Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia.","volume":"26","author":"Tewari","year":"2006","journal-title":"Retina"},{"key":"R17-8-20210130","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1038\/eye.2008.404","article-title":"Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up.","volume":"23","author":"Wu","year":"2009","journal-title":"Eye"},{"key":"R18-8-20210130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/bjo.2006.096776","article-title":"Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia.","volume":"91","author":"Yamamoto","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R19-8-20210130","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ajo.2005.10.012","article-title":"Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization.","volume":"141","author":"Tong","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R20-8-20210130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ajo.2007.03.043","article-title":"The risk of retinal detachment in high myopia after small incision coaxial phacoemulsification.","volume":"144","author":"Alio","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R21-8-20210130","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin).","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"R22-8-20210130","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0161-6420(96)30515-0","article-title":"Etiology of choroidal neovascularization in young patients.","volume":"103","author":"Cohen","year":"1996","journal-title":"Ophthalmology"},{"key":"R23-8-20210130","doi-asserted-by":"crossref","first-page":"278","DOI":"10.5483\/BMBRep.2008.41.4.278","article-title":"Vascular endothelial growth factor-dependent and independent regulation of angiogenesis.","volume":"41","author":"Shibuya","year":"2008","journal-title":"BMB Rep"},{"key":"R24-8-20210130","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/bjo.2008.147611","article-title":"Photodynamic therapy may worsen the prognosis of highly myopic choroidal neovascularisation treated by intravitreal bevacizumab.","volume":"93","author":"Ruiz-Moreno","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R25-8-20210130","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.ophtha.2009.08.004","article-title":"Angiographic changes after bevacizumab.","volume":"116","author":"Ikuno","year":"2009","journal-title":"Ophthalmology"},{"key":"R26-8-20210130","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0161-6420(01)00544-9","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report no. 1.","volume":"108","year":"2001","journal-title":"Ophthalmology"},{"key":"R27-8-20210130","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ajo.2009.03.026","article-title":"Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy.","volume":"148","author":"Hayashi","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R28-8-20210130","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ajo.2009.08.008","article-title":"Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization.","volume":"149","author":"Ikuno","year":"2010","journal-title":"Am J Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0b013e3181e22659","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:43:53Z","timestamp":1620956633000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201011000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e3181e22659","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}